Business Context and Reporting Period
Company: Oruka Therapeutics, Inc. (formerly ARCA biopharma, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: August 29, 2024 (Closing Date)
Event: Consummation of a business combination (Merger) between ARCA biopharma, Inc. and Oruka Therapeutics, Inc. (private). ARCA changed its name to Oruka Therapeutics, Inc. and ceased to be a shell company.
Key Financial Metrics and Capitalization
Pre-Closing Financing: Oruka raised approximately $275.0 million in gross proceeds immediately prior to the Closing. This included the issuance of 39,873,706 shares of Oruka Common Stock and 9,664,208 pre-funded warrants. The proceeds included $25.0 million from a previously issued Convertible Note.
Special Dividend: On August 28, 2024, the Company paid a special cash dividend of approximately $23.4 million ($1.613 per share) to ARCA stockholders of record.
Post-Merger Capitalization (Pre-Reverse Split):
- ARCA securityholders own approximately 2.39% of the combined company.
- Oruka securityholders (including Pre-Closing Financing investors) own approximately 97.61% of the combined company.
Share Structure:
- Exchange Ratio: 6.8569 shares of ARCA Common Stock for each share of Oruka Common Stock.
- Reverse Stock Split: A 1-for-12 reverse stock split was effected on September 3, 2024.
- Outstanding Shares (Post-Split): Approximately 29,398,595 shares of Common Stock outstanding (excluding preferred stock and employee awards).
Financial Statements: The filing incorporates unaudited interim condensed consolidated financial statements of Oruka as of June 30, 2024, and audited financial statements as of February 6, 2024. Specific revenue, profit, or cash flow figures for the combined entity are not provided in this text; they are referenced in attached exhibits (99.3, 99.4, 99.5).
Material Changes Versus Prior Period
- Corporate Identity: The registrant changed its name from ARCA biopharma, Inc. to Oruka Therapeutics, Inc.
- Shell Status: The Company transitioned from a shell company status to an operating biopharmaceutical company.
- Ownership Structure: Control shifted significantly to Oruka's former shareholders and new financing investors, who now hold ~97.6% of the equity.
- Accounting Firm: KPMG LLP was dismissed as the independent registered public accounting firm on August 30, 2024. PricewaterhouseCoopers LLP (PwC) was appointed as the new auditor.
- Management Changes:
- Appointments: Lawrence Klein appointed President and CEO; Arjun Agarwal appointed SVP of Finance and Treasurer; Joana Goncalves appointed CMO; Paul Quinlan appointed General Counsel.
- Departures: Former ARCA executives Thomas A. Keuer (COO) and C. Jeffrey Dekker (CFO) resigned. Dekker entered a consulting agreement for transition services.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Strategy: The Company is focused on advancing product candidates through preclinical and clinical development. It has entered into "Antibody Discovery and Option Agreements" with Paragon Therapeutics, Inc., granting Oruka exclusive options to license antibodies for specific therapeutic targets. No options have been exercised as of the filing date.
Risks and Contingencies:
- Development Risk: Limited operating history and reliance on the success of preclinical and clinical trials.
- Capital Needs: Significant risk regarding the ability to raise additional capital to finance operations.
- Regulatory Risk: Dependence on FDA approval and manufacturing compliance.
- Forward-Looking Statements: The filing contains standard cautionary notes that actual results may differ materially from expectations due to various factors including competition and market acceptance.
Unusual Items:
- Lock-Up Agreements: Certain Oruka executives, directors, and stockholders are subject to 180-day lock-up agreements restricting the sale of shares.
- Severance: Departing ARCA executives received severance packages including 12 months of base salary and health insurance premiums.
Important Facts for Investor Verification
- Trading Symbol Change: Verify the ticker symbol change from "ABIO" to "ORKA" on The Nasdaq Global Market, effective September 3, 2024.
- Reverse Stock Split: Confirm the 1-for-12 reverse stock split adjustment on share counts and price history.
- Capitalization: Verify the post-merger ownership split (approx. 97.6% Oruka/Financing Investors vs. 2.4% legacy ARCA).
- Financial Health: Review the attached unaudited pro forma financial information (Exhibit 99.5) to assess the combined company's cash position and burn rate, as this 8-K does not list specific revenue or net income figures.
- Equity Dilution: Note the existence of 5,522,207 pre-funded warrants and 11,428,166 shares underlying preferred stock that could impact future dilution.
- Management Transition: Confirm the new leadership team's experience and the status of the transition services provided by the former CFO.